We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Concert Pharmaceuticals

News List

Concert Pharmaceuticals announces plans for CTP-543 phase 3 trials in alopecia areata pharmaceutical-business-review
April 06, 2020
Concert Pharmaceuticals announced the details of its pivotal Phase 3 trials of CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss.
Concert Pharmaceuticals Announces Initiation of Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata pharmafocusasia
March 07, 2019
Concert Pharmaceuticals, Inc. today announced that it has initiated an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.
Concert Pharmaceuticals initiates CTP-543 Phase II trial in alopecia areata cphi-online
May 05, 2017
Trial designed to evaluate the safety and efficacy of CTP-543 after 12 months of dosing with the primary efficacy analysis at week 24.
Vertex to acquire Concert Pharmaceuticals’ cystic fibrosis drug for $250m pharmaceutical-technology
March 08, 2017
US-based Vertex Pharmaceuticals has signed an agreement to acquire CTP-656, an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator from Concert Pharmaceuticals for up to $250m.